Department of Obstetrics and Gynecology, The University of Texas Health Science Center at San Antonio, 78229, USA.
IUBMB Life. 2010 Mar;62(3):162-9. doi: 10.1002/iub.287.
Recent studies implicate that the estrogen receptor (ER) coregulator proline-, glutamic acid-, and leucine-rich protein (PELP) 1 as playing critical roles in ER-genomic, ER-nongenomic, and ER-signaling cross talk with growth factor signaling pathways. PELP1 expression is deregulated in hormonal cancers and recent studies further elucidated the molecular mechanisms by which PELP1 regulates hormone therapy response. Although PELP1 is important for normal functions of the ER, the possibility to target ER-PELP1 axis appears to be an effective strategy for preventing hormonal carcinogenesis and therapy resistance. Thus, PELP1 may be useful as prognostic marker for hormonal cancers and PELP1 signaling may be useful to generate targeted therapeutics to overcome hormonal therapy resistance.
最近的研究表明，雌激素受体（ER）辅助调节蛋白脯氨酸、谷氨酸和亮氨酸丰富蛋白（PELP）1 在 ER-基因组、ER-非基因组和 ER 信号与生长因子信号通路的交叉对话中发挥着关键作用。PELP1 的表达在激素癌中失调，最近的研究进一步阐明了 PELP1 调节激素治疗反应的分子机制。虽然 PELP1 对 ER 的正常功能很重要，但靶向 ER-PELP1 轴的可能性似乎是预防激素致癌和治疗耐药的有效策略。因此，PELP1 可能是激素癌的有用预后标志物，PELP1 信号可能有助于生成靶向治疗药物以克服激素治疗耐药性。
